Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions for cellular homeostasis, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a caloric source and may reduce protein catabolism. Sodium chloride 0.45% provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
IV infusion at a rate dependent on patient's fluid and electrolyte needs; typical adult maintenance: 1000-2000 mL/day, providing 20-40 mEq potassium per liter.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: terminal half-life approximately 12 hours (3-compartment model), but distribution phase ~1 hour; clinical context: steady-state reached in 2-3 days.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: primarily renal (>90%) via distal tubule secretion; minimal fecal. Chloride: renal reabsorption/excretion linked to sodium. Dextrose: metabolized to CO2 and water; <2% renal. Sodium: renal excretion regulated by aldosterone.
Category C
Category A/B
Electrolyte
Electrolyte